Transforming Patient Experience

VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) applied to the buccal surface, being developed for the treatment of people suffering from treatment-resistant depression (TRD).Pharmacologically, VLS-01 is a partial to full agonist of the 5-HT1/2/6/7 sub-receptors and is being developed to potentially offer rapid, robust, and durable efficacy with a favorable safety profile. VLS-01 is designed to fit within the established two-hour interventional psychiatry treatment paradigm, positioning it for integration into existing care models.

Nualtis is developing a buprenorphine/naloxone sublingual film as a generic alternative for the treatment of opioid dependence. Utilizing its VersaFilm® platform, the formulation is designed to deliver reliable dosing and support patient adherence in medication-assisted treatment programs. The program aims to expand access to effective, evidence-based therapies in an established market by providing a high-quality, cost-efficient product.

Rizatriptan is a fast-acting, selective serotonin 5-HT。/1D receptor agonist used for the acute treatment of migraines, with or without aura. By targeting specific receptors in the brain, rizatriptan helps constrict dilated blood vessels and block pain pathways, offering rapid relief from migraine symptoms such as headache, nausea, and light sensitivity.

It is typically well tolerated and is favoured for its quick onset of action compared to other triptans. This molecule is available both as a standard tablet and as an orally disintegrating tablet (ODT), providing flexible administration options.

Rizatriptan represents a well-established therapeutic class with continued relevance in markets seeking fast and effective migraine interventions.

Nualtis is developing Montelukast oral film as a novel therapeutic platform for neurodegenerative diseases, focusing on its neuroprotective and anti-inflammatory potential. Building on positive Phase 2a safety and feasibility data in Alzheimer’s disease, the company—together with Karolinska Institutet—is advancing the MONTPARK Phase 2 trial in early-to-moderate Parkinson’s disease, led by Professor Per Svenningsson and funded by the Swedish Research Council. This 18-month, multicenter, randomized, double-blind, placebo-controlled study evaluates high-dose Montelukast VersaFilm® targeting neuroinflammation as a potential disease-modifying pathway. With its patient-friendly oral film format designed to enhance compliance and brain bioavailability, Nualtis is positioning Montelukast as a leading candidate in the global search for disease-modifying therapies in neurodegeneration.

Nualtis is advancing the development of a tadalafil oral film, leveraging its proprietary VersaFilm® technology to deliver a discreet, convenient, and fast-acting alternative to conventional tablets. The program targets the erectile dysfunction market, where improved patient compliance and differentiated delivery formats create strong commercial potential. The oral film is designed for rapid dissolution without water, providing ease of use and portability.